Tnf antagonists
AssigneeAnaphore, Inc.
InventorsHelle Krogh Ottow, Mette Munch, Thor Las Holtet, Mikkel Holmen Andersen, Josephus Dirk Nieland
Life of this patent
Estimating the term…
Abstract
TNF binding polypeptides based on human tetranectin C-type lectin like domains (CTLD) with improved binding characteristics and improved efficacy. The polypeptides comprise a TNF binding domain having the amino acid sequence KRWS-RYF (SEQ ID NO:1). Also provided are methods of preparing the polypeptides of the invention. The polypeptides may be used for the preparation of pharmaceutical compositions, and for treatment of a subject having a pathology mediated by TNF, such as treatment of rheumatoid arthritis.
Claims27
A polypeptide capable of binding tumour necrosis factor (TNF), where said polypeptide comprises the amino acid sequence KRWSRYF (SEQ ID NO:1).
Dependencies are inferred from the claim text.